Natco Pharma Gets US FDA EIR for Its Visakhapatnam Plant
The US FDA classified the August 2026 inspection of Natco Pharma's Parawada, Visakhapatnam formulations facility as Voluntary Action Indicated.
Key Takeaways
- Natco Pharma received a US FDA EIR for its Parawada, Visakhapatnam FDF facility.
- The US FDA classified the inspection as Voluntary Action Indicated (VAI).
- The inspection ran from August 17 to August 21, 2026.
- It ended with a Form 483 carrying four observations.
- Natco disclosed the EIR to the stock exchanges on November 20, 2026.
Table of Contents 5 sections
Natco Pharma has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its Finished Dosage Formulations (FDF) manufacturing facility at Parawada, Visakhapatnam, in Andhra Pradesh. The Hyderabad-based drug maker told the stock exchanges about it on November 20, 2026.
The EIR covers a US FDA inspection of the plant held from August 17 to August 21, 2026. That inspection ended with a Form 483 carrying four observations, which Natco disclosed on August 21. The US FDA has now classified the inspection as Voluntary Action Indicated (VAI), which means the regulator found conditions that call for voluntary corrective action by the company.
Natco Pharma's Visakhapatnam EIR at a glance
| Detail | Value |
|---|---|
| Company | Natco Pharma Ltd |
| Facility | Finished Dosage Formulations (FDF) manufacturing facility |
| Location | Parawada, Visakhapatnam, Andhra Pradesh |
| Inspection dates | August 17 to August 21, 2026 |
| Form 483 observations | Four |
| Classification | Voluntary Action Indicated (VAI) |
| Disclosed to exchanges | November 20, 2026 |
How the August inspection led to a VAI rating for Natco's Vizag plant
When the August inspection ended, Natco said it believed the four observations were procedural in nature and that it was confident of addressing them within the stipulated timelines. The EIR now received from the US FDA communicates the VAI classification for that inspection.
Natco is headquartered in Hyderabad. The company says its facilities are approved by regulators including the US FDA, Brazil's ANVISA, Health Canada and the WHO, and that it serves more than 50 global markets.
Natco's US FDA inspections at its Visakhapatnam formulations facility
| When | What happened |
|---|---|
| March 24 to March 30, 2020 | US FDA inspected Natco's drug formulations facility at Visakhapatnam |
| May 2020 | Natco received an EIR for that inspection |
| January 30 to February 3, 2023 | US FDA inspection ended with two observations, one on written production process control procedure and one on investigation procedure |
| June 2023 | Natco received an EIR closing the 2023 inspection |
| August 17 to August 21, 2026 | US FDA inspected the Parawada FDF facility and issued a Form 483 with four observations |
| November 20, 2026 | Natco disclosed the EIR with a VAI classification |
Where Natco Pharma's Visakhapatnam plant stands after the EIR
Natco Pharma's Parawada, Visakhapatnam FDF facility now has an EIR from the US FDA, with the August 2026 inspection classified as Voluntary Action Indicated. The inspection had ended with four Form 483 observations, which the company said it believed were procedural in nature. Natco had earlier received EIRs for its drug formulations facility at Visakhapatnam in May 2020 and June 2023.
More news
Frequently Asked Questions
What is Natco Pharma?
What did Natco Pharma receive from the US FDA?
Which Natco Pharma facility does the EIR cover?
When was Natco Pharma's Visakhapatnam facility inspected?
How many observations did Natco Pharma get in the inspection?
How did the US FDA classify Natco Pharma's inspection?
What does the VAI classification mean for Natco Pharma?
When did Natco Pharma disclose the EIR?
How did Natco Pharma describe the four observations?
When did Natco Pharma receive earlier EIRs for Visakhapatnam?
How many observations did Natco Pharma get in the 2023 inspection?
How many markets does Natco Pharma serve?
More in Business
Amazon Prime India Head Abhinav Agarwal Leaves After 16 Years
Amazon Prime India head Abhinav Agarwal has left Amazon after 16 years at the company.
Waaree Transpower Wins Over Rs 100 Crore Order From NTPC
Waaree Transpower will supply 11 MVA to 22 MVA transformers for NTPC's battery storage project.
Adani Energy Solutions Wins a Bihar Transmission Project
Adani Energy Solutions has won a Bihar transmission project linked to the Pirpainti power plant.
